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Abstract We describe here Ro 46-8443, the first non-peptide 
endothelin ETn receptor selective antagonist. It displays up to 
2000-fold selectivity for ET n receptors both in terms of binding 
inhibitory potency and functional inhibition. The observed 
parallel rightward shift of concentration-response curves with 
different antagonist concentrations i  consistent with a compet- 
itive binding mode. Since Ro 46-8443 selectively inhibits ETa 
receptor mediated responses, it is a valuable tool for clarifying 
the role of ETB receptors in pathology. 
l~,y words: Endothelin; Endothelin antagonist; Endothelin 
g FB receptor; Endothelin ETA receptor 
1. Introduction 
Endothelins (ET-1, ET-2 and ET-3) are a family of 21-ami- 
n ) acid peptides, which contain two disulfide bridges between 
p)sitions 1-15 and 3 11 and six highly conserved amino acid 
rt~sidues at the carboxyl terminus [1]. ET-1 represents he most 
p)tent vasoconstrictor known to date. It binds on at least two 
s~tbtypes of G-protein coupled receptors with seven trans- 
membrane spanning domains, named ETA [2] and ETB recep- 
t,,r [3]. ETA receptors electively bind ET-1 and ET-2, whereas 
[ l ' s  receptors display similar potency for all three isopep- 
t~des. The profound vasoconstriction is mediated both by 
[-I'A and ETB receptors located on smooth muscle cells [4- 
6. In addition, ETB receptors located on endothelial cells are 
a,~le to mediate vasodilatation through release of endothelium 
d, erived relaxing factor or prostacyclin [7]. Interestingly, cer- 
tdn  pathological situations have been associated with in- 
c "eased density of ETB receptors [8-11], but the lack of ETB 
r'ceptor selective antagonists has hampered further elucida- 
t on of the role of ETt~ receptors in pathology. 
Peptidic agonists with selectivity for ETB receptors, like 
[ \Ial,3,11,1'~]ET-1 [ 2], sarafotoxin S6c [13], BQ 3020 [14] and 
I~IL 1620 [15] and recently also peptidic ETB receptor selec- 
t ve antagonists, e.g. IRL 1038 [16], BQ 788 [17] and RES 701 
[ 8] have been described. Among these antagonists, BQ 788 
r ~veals only a low selectivity for ETB on human ET receptors, 
I RL 1038 lacks chemical stability [19] and the synthetic form 
f RES 701 is much less potent than the naturally occurring 
I eptide [20]. Yet, for studying the role of ETB receptors in 
l athology, chemically stable and selective ETB receptor an- 
t tgonists are essential. The present paper describes Ro 46- 
b443, the first non-peptide ETB receptor selective antagonist. 
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2. Materials and methods 
2.1. Materials 
[12~I]ET-1 and [125I]sarafotoxin S6c were obtained from Anawa 
(Wangen, Switzerland). ET-I, ET-2, ET-3 were purchased from No- 
vabiochem AG (L/iufelfingen, Switzerland}. [3H][Arachidonic 
acid ~,6,s,9'11,12,14,1~] was from Amersham (Rahn AG, Ziirich, Switzer- 
land). Phosphoramidon was purchased from Sigma, Bio-Science Pro- 
ducts AG (Emmenbrticke, Switzerland). Ro 46-8443 and BQ 788 were 
synthesized at Hoffmann-La Roche AG (Basel, Switzerland). As ref- 
erence compounds, RES 701-1, RES 701-3 and IRL 1038 were pur- 
chased from Alexis Corporation (LS.ufelfingen, Switzerland). In addi- 
tion, IRL 1038 was also bought from Neosystem (Strasbourg, 
France). Human placentas were obtained from a local maternity hos- 
pital and porcine trachea was obtained from the local slaughterhouse. 
All tissues were stored at -80°C. Culture reagents were purchased 
from Gibco Laboratories (Paisley, Scotland). 
2.2. Chemical synthesis of Ro 46-8443 
(R)-4-tert-Butyl-N-[6-(2,3 -dihydroxy-propoxy)-5-(2-methoxy-phen- 
oxy)-2-(4-methoxy-phenyl)-pyrimidin-4-yl]-benzenesulfonamide was 
prepared by treatment of 4,6-dichloro-5-(2-methoxy-phenoxy)-2-(4- 
methoxy-phenyl)-pyrimidine w th p-tert-butylbenzolsulfonamide po- 
tassium salt in acetonitrile to give 4-tert-butyl-N-[6-chloro-5-(2-meth- 
oxy-phenoxy)-2-(4-methoxy-phenyl)-pyrimidin-4-yl]-benzenesulfona- 
mide which was further reacted with (S)-l,2-di-O-isopropylidene- 
glycerol and sodium hydride in dimethyl sulfoxide to give (S)-4-tert- 
butyl-N-[6-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-5-(2-methoxy- 
phenoxy)-2-(4-methoxy-phenyl)-pyrimidin-4-yl]-benzenesulfonamide. 
Subsequently deprotection was achieved with 1 N aqueous HC1 in 
dioxane to give Ro 46-8443. 
2.3. Cell culture 
Rat mesangial cells, baculovirus infected insect cells (Sf9 cells), 
CHO cells and human vascular smooth muscle cells, obtained from 
umbilical veins, were cultured as described previously [21]. 
2.4. Preparation oJ membranes 
Microsomal membranes were prepared as described earlier [22] 
from human placenta, porcine trachea, rat trachea, baculovirus in- 
fected insect cells expressing recombinant human ETA receptor and 
CHO cells expressing recombinant ETB receptor cloned from human 
placenta [23,24], and stored in aliquots at -80°C. Protein was deter- 
mined according to the method of Lowry [25]. 
2.5. Competition binding assays 
Competition binding assays on ETA receptors were performed on 
membrane preparations of baculovirus infected insect cells expressing 
human recombinant ETA receptor and on attached human smooth 
muscle cells or rat mesangial cells using [125I]ET-1 as radiolabelled 
ligand. Binding assays on ETB receptors were also performed in the 
presence of [125I]ET-1 using membranes of CHO cells expressing hu- 
man recombinant ETB receptor or membranes of human placenta. 
Membranes of porcine or rat trachea were used for binding studies 
on ETB receptors mediating constriction. Since rat and porcine tra- 
chea contain both ETA and ETl3 receptors, the ETB selective agonist 
[12~I]sarafotoxin S6c was used as labelled ligand in these experiments. 
Binding assays on membranes were performed in 250 ~tl 50 mM 
Tris buffer (pH 7.4, 25 mM MnC12, 1 mM EDTA, 0.5% (w/v) BSA) 
containing 0.1-35 ~g protein, 32 pM lzZI-labelled ligand and increas- 
ing amounts of unlabelled antagonists. After incubation for 2-3 h at 
22°C, bound and free ligand were separated by filtration. 
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Fig. 1. Structure of Ro 46-8443, (R)-4-tert-butyl-N-[6-(2,3-dihy- 
droxy-propoxy)-5-(2-methoxy-phenoxy)-2-(4-methoxy-phenyl)-pyrimi- 
din-4-yl]-benzene-sulfonamide. 
Binding assays with whole attached cells were performed in 500 ~tl 
Dulbecco's Eagle medium (DMEM) containing 2 mg/ml BSA and 25 
mM Hepes. After incubation (2 h, 22°C) in the presence of 35 pM 
[125I]ET-1 and increasing concentrations of Ro 46-8443, the cells were 
extensively washed and finally solubilized in I% (w/v) SDS, 0.5 M 
NaOH, 100 mM EDTA. 
Each assay was performed three times in triplicate and non-specific 
binding was assessed in the presence of 100 nM unlabelled ET-1. 
Specific binding was defined as the difference between total binding 
and non-specific binding. ICso values were determined after logit/log 
transformation f the binding data. 
2.6. Measurement of  arachidonic acid release 
[aH]Arachidonic acid release was measured by a modification of the 
method of Felder et al. [26]. Confluent CHO cells grown in 24 well 
plates, expressing recombinant human ETB receptor, were incubated 
for 24 h with [3H]arachidonic acid (1 ~tCi/well), washed three times 
with DMEM supplemented with 2 mg/ml bovine serum albumin, 25 
mM Hepes, pH 7.4 and incubated in this medium for 30 min at 370C. 
After an additional washing step the reaction was started by replacing 
the buffer with fresh medium containing varying amounts of sarafo- 
toxin S6c and Ro 46-8443. All incubation and washing steps were 
performed in the presence of phosphoramidon (100/.tM). After incu- 
bation, the supernatant from each well was removed and centrifuged 
(10 min, 1100 rpm) to sediment detached cells. Finally, 
[aH]arachidonic a id release into the incubation medium was quanti- 
fied by liquid scintillation counting. Three experiments were per- 
formed in triplicate. Data are presented as mean + standard error of 
the mean (S.E.M.). 
2.7. Functional inhibition of contracthm 
2. 7.1. Isolated rat aortic rings. In isolated rat aortic rings denuded 
of their endothelium, contractions induced by ET-I are mediated 
through ETA receptors. Male 14-16 week old Wistar-Kyoto rats 
were anesthetized with Inactin (sodium thiobutabarbital, 100 mg/kg 
intraperitoneally), the thoracic aorta was removed and cut into 5 mm 
rings. The endothelium was removed by gentle rubbing of the intimal 
surface, and each ring was suspended in a 10 ml isolated organ cham- 
ber containing assed (95% OJ5% COs) and warmed (37°C) Krebs- 
Henseleit solution of the following composition, in mM: NaC1 115, 
KC1 4.7, MgSO4 1.2, KHPO4 1.5, NaHCO3 25, CaC12 2.5 and glucose 
10. Isometric force was recorded. The rings were stretched to a resting 
force of 3 g. After a 60 min equilibration period, the rings were 
contracted using norepinephrine (10 -7 M). Endothelium denudation 
was assessed by the absence of relaxation to acetylcholine (10 -5 M). 
The rings were then washed and stretched if necessary until a stable 
baseline force was obtained. The rings were incubated with various 
concentrations (3x 10 -6 to 1 × 10 -4 M) of Ro 46-8443. After 10 min, 
cumulative doses of ET-1 were added, the interval between doses was 
determined by the time required for the force generated to reach a 
plateau. 
2. 7.2. Isolated rat tracheal rings. In rat tracheal rings denuded of 
epithelium, the contractions induced by sarafotoxin S6C are mediated 
through smooth muscle ETB receptors. Male rats were anesthetized, 
the trachea was removed and cut into 5 mm rings. The epithelium was 
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removed by gentle rubbing of the luminal surface, and each ring was 
suspended in a 10 ml isolated organ chamber containing assed and 
warmed Krebs-Henseleit solution as described above. The rings were 
stretched to a resting force of 2 g. After a 60 min equilibration period, 
the rings were contracted using potassium chloride (50 mM) and 
washed afterwards. After a 10 min incubation with Ro 46-8443 
(3× 10 -7 to 1 ×10 -5 M), cumulative doses of sarafotoxin S6C were 
added, the interval between doses was determined by the time re- 
quired for the force generated to reach a plateau. 
2.Z3. Analysis and calculations. The maximum force was defined 
as the force generated with the highest concentration yielding a max- 
imal effect, and from this the ET-1 or sarafotoxin S6C concentration 
yielding a half-maximal effect (ECs0) was calculated. The pA2 value 
(negative logarithm of the molar concentration of antagonist which 
causes a twofold parallel shift to the right of the agonist concentra- 
tion-response curve), as an index of potency, was determined for each 
individual curve by the equation pA2 = log (concentration rat io -1) -  
log [B], where concentration ratio is the ratio of ECs0 values with/ 
without antagonist and [B] the concentration of antagonist. Regres- 
sion analysis of the plot log (concentration rat io- l )  against log [B] 
(Schild plot) allowed to confirm the competitive nature of the antago- 
nist by assessing its slope [27]. 
3. Results 
On ETA receptor preparations, Ro 46-8443, a pyrimidyl 
sulfonamide (Fig. 1), displayed a binding potency in the IxM 
range. It competed for the binding of [12SI]ET-1 on cultured 
human vascular smooth muscle cells, rat mesangial cells and 
membranes of baculovirus infected insect cells expressing hu- 
man recombinant ETA receptor esulting in monophasic om- 
petit ion binding curves with average ICs0 values of 2.2, 0.9 
and 6.8 ~tM (Fig. 2), respectively. 
Consistently higher potency was observed for ETB receptor 
preparations. Ro 46-8443 competed for the binding of 
[125I]ET-1 on membranes of CHO cells carrying recombinant 
human ETB receptor and microsomal membranes from hu- 
man placenta with monophasic binding curves resulting in 
ICs0 values of 69 nM and 34 nM, respectively (Fig. 2). Mem- 
branes of porcine or rat trachea, a tissue which responds by 
constriction when stimulated with ETB selective agonists like 
~. .100-  ~. ~ - - _- - -  _- 
"o  80-  c"' 
"-,z 
o 70-  
,.Q 
-o  60-  
c- 
co 50-  
• "o 40-  
_ --~ 30-  
a~ 
-Q  20-  
lO -  
0 I I I I I I I T 1 ~IF "P" "~/ 1~,4 "IP '
- '10  "9  "8  -7  "6  "5  -4  
LOG (Ro 46-8443, M) 
Fig. 2. Competition binding curves with Ro 46-8443: using either 
[125I]ET-1 and (ll) membranes of baculovirus infected insect cells ex- 
pressing human ETA receptor, ( • ) membranes of CHO cells expres- 
sing human ETB receptor and (O) membranes of human placenta 
carrying mainly ETB receptor, or [12~I]sarafotoxin S6c and ((3) mem- 
branes of porcine trachea. Values are means + standard eviation of 
at least three independent experiments performed in triplicates. 
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~arafotoxin $6c, were used to assess the binding inhibitory 
potency of Ro 46-8443 on 'constricting' ETB receptors. In 
I hese binding assays, Ro 46-8443 competed for the ETB selec- 
tive agonist [125I]sarafotoxin $6c with IC50 values of 4.9 (Fig. 
2) and 3.2 nM, respectively. Thus, Ro 46-8443 displays 300- 
:'.000-fold selectivity for these constricting ETB receptors over 
the above mentioned ETA receptor preparations. In order to 
profile Ro 46-8443 against previously described peptidic ET 
~mtagonists, the potencies of RES 701-1, RES 701-3, BQ 788 
:rod finally IRL 1038 from two different purchasers were as- 
.essed on recombinant human ETA receptor expressed on ba- 
, ulovirus infected insect cells and ETB receptor on membranes 
irom human placenta. In these assays, both IRL 1038 batches 
did not show any potency up to 10 gM, BQ 788 displayed 
iCs0 values of 3.8 [aM on ETA receptor and 47 nM on ETB 
receptor and RES 701-1 or RES 701-3 showed IC50 values of 
120 or 45 gM on ETA receptor and 17 or 11 [aM on ETB 
receptor. 
In order to characterize the functional inhibition of ETB 
-eceptors, we studied the ET receptor mediated release of 
39 
arachidonic acid from CHO cells carrying recombinant hu- 
man ETB receptor. Upon stimulation with sarafotoxin $6c, 
we obtained a time and concentration dependent release of 
[aH]arachidonic acid with an apparent ECs0 value of 
250+ 110 pM (Fig. 3A), which reached a plateau after 20 
min. The maximal response represented a 15-fold stimulation 
over the basal release of [aH]arachidonic acid. Ro 46-8443 
dose dependently inhibited this response with an apparent 
ICs0 value of 110+30 nM (Fig. 3B). 
The potency of Ro 46-8443 to inhibit the sarafotoxin $6c 
mediated constriction of rat tracheal rings was also assessed as 
a measure of functional inhibitory potency on ETB receptors. 
Ro 46-8443 caused a dose dependent parallel rightwards hift 
of the dose response curves resulting in a pA2 value of 
7.1 + 0.2 (Fig. 4). The ET-1 induced constriction of rat aortic 
rings, mediated via ETA receptors, was inhibited with a pA2 
value of 5.7 + 0.06. 
In all functional assays, Ro 46-8443 was devoid of any 
agonistic activity. 
4. Discuss ion 
Endothelin induced constriction may play a key role in a 
variety of diseases uch as bronchial asthma, pulmonary hy- 
pertension, congestive heart failure, renal failure or subarach- 
noidal hemorrhage (for review, see [28]). It has been demon- 
strated that not only ETA but also ETB receptors can mediate 
vaso- or bronchoconstriction [4-6]. Furthermore, the impor- 
tance of ETB receptors in pathological situations may be re- 
flected by enhanced receptor densities as recently described for 
the aorta of spontaneously hypertensive rats [9], the basilar 
artery of rabbits after subarachnoidal hemorrhage [11] and for 
the rabbit carotid artery after balloon denudation [29]. Most 
recently, an upregulation of ETB receptors has also been dem- 
onstrated in human coronary arteries from atherosclerotic 
patients [10]. In order to further characterize the nature of 
these ETB receptors and to clarify the role of ETB receptors 
in pathology, ETB receptor selective antagonists are an essen- 
tial tool. Unfortunately, recently described ETB receptor se- 
lective peptidic antagonists seem to be of limited value, either 
because the activity of the natural product differs from the 
chemically synthesized form, as it has been demonstrated for 
RES 701 or because of limited stability of the antagonist, as in 
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Fig. 4. Effect of Ro 46-8443 (e) 0.3 gM, (A) i gM and (0 )  10 
gM or its vehicle (DMSO, II) on the concentration-response curves 
of sarafotoxin $6c mediated contraction in isolated rat trachea with- 
out epithelium. 
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the case of IRL 1038. This is in line with our observations 
that RES 701-1 as well as IRL 1038 from two different 
sources displayed only potency in the ~tM range and hardly 
any ETB receptor selectivity in binding assays with human ET 
receptors. Similar observations from other laboratories re- 
suited in withdrawal of IRL 1038 [19]. In our assay systems, 
also the ETB receptor potency (IC~0:48 nM) and selectivity 
(80-fold) of BQ 788 proved to be less favorable than pre- 
viously published data describing an IC50 of 1.2 nM on 
ETB receptors and a more than 1000-fold ETB selectivity 
for human receptors [17]. Possible explanations for this dis- 
crepancy include the use of different assay systems or proteo- 
lytic degradation of the compound. 
The issue of correct protein folding and stability is a well 
known drawback of peptidic ligands and provides a strong 
motivation for the development of non-peptide antagonists. 
This paper characterizes the in vitro properties of Ro 46- 
8443, which is to our knowledge the first non-peptide ETB 
receptor selective antagonist. 
Ro 46-8443, a sulfonamide with central pyrimidine moiety, 
is structurally related to the recently described antagonists Ro 
46-2005 [22,30] and bosentan [21], which bind to both ETA 
and ETB receptors with comparable potency. However, re- 
placement of the second pyrimidine, found in the bosentan 
structure, by a p-methoxy-phenyl moiety and replacement of 
the hydroxy-ethoxy side chain by a glycerol residue resulted in 
an ETB receptor selective antagonist. In competition binding 
assays with human ET receptors, Ro 46-8443 displayed an at 
least 100-fold selectivity for ETB (IC50:34-69 nM) over ETA 
receptors (1C50 : 6800 nM). This selectivity ratio reaches values 
of more than 2000, if the potency on constricting ETB recep- 
tors, i.e. the potency on membranes of rat or porcine trachea, 
is considered. Unfortunately, so far no data with correspond- 
ing human constricting ETB receptors are available. Efforts to 
measure sarafotoxin $6c mediated constriction in human 
atherosclerotic coronary arteries failed due to the occurrence 
of spontaneous phasic constrictions [10]. However, because 
similar binding potency and selectivity ratio was found be- 
tween human and rat ETA and ETB receptors, Ro 46-8443 
seems to display few if any species differences, suggesting a 
highly conserved binding site on the ET receptors. Establish- 
ing the differences of this interaction to the recently described 
binding site of bosentan [31] will be valuable for the future 
design of new ETB receptor selective antagonists. 
The observed binding potency of Ro 46-8443 on human 
ETB receptors expressed in CHO cells translated well into 
the potency for functional inhibition of sarafotoxin $6c in- 
duced release of arachidonic acid. In addition, no agonistic 
activity of Ro 46-8443 was observed in the absence of sara- 
fotoxin $6c suggesting that Ro 46-8443 binds to the inactive 
conformation of the ETB receptor. 
The observation that Ro 46-8443 also inhibited the sarafo- 
toxin $6c mediated contraction of rat tracheal rings demon- 
strates its potency to inhibit constricting ETB receptors and 
shows its capability for tissue penetration, enabling the com- 
pound to reach the smooth muscle cells in the media. Differ- 
ences in the ability for tissue penetration and protein binding 
in rat aortic rings and rat tracheal rings may account for the 
somewhat lower ETB receptor selectivity in these functional 
assays. The parallel rightwards hift of the concentration re- 
sponse curve by different Ro 46-8443 concentrations is in line 
with a competitive interaction with the ETB receptor. 
Overall, its non-peptidic nature, potency and ETB receptor 
selectivity make Ro 46-8443 a unique tool which may make it 
possible to explore the role of ETB receptors in different ani- 
mal models such as hypertension [32]. 
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